ReviewAdvances in biochemical engineering/biotechnology2026
Continuous Crystallization Platforms to Crystallize Biomolecules.
Review in Advances in biochemical engineering/biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the realm of industrial crystallization for biomolecules, batch crystallizers have been the predominant platform, although continuous crystallizers with clearly superior performances have been actively investigated in recent years. Among them, mixed-suspension-mixed-product-removal crystallizer (MSMPRC), plug flow crystallizer (PFC), slug flow crystallizer (SFC), oscillatory flow baffled crystallizer (OFBC), and other innovative continuous platforms such as membrane crystallizer and Couette-Taylor (CT) crystallizer are introduced in this chapter. These crystallizers have been utilized in continuous crystallization of biomolecules including globular proteins such as lysozyme and insulin. Their key design variables encompassing variables affecting kinetics (residence time distribution (RTD), mixing strategy, etc.) and variables affecting thermodynamics (driving force of crystallization) are discussed. As a promising alternative to conventional chromatography method, continuous crystallization shows great potential for downstream processing of biomolecules.
Indexed as
Identifiers
41820683What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.